

## Chemoprophylaxis for HIV Prevention in Peruvian Men

**Project Staff:** Gladstone Institute of Virology and Immunology: Robert Grant, Vivian Levy, Jeff McConnell, Vanessa McMahan; UCSF: Kimberly Page-Shafer, David Glidden; IMPACTA: Javier Lama, Pedro Goicochea, Juan Guanira, Lorena Vargas, Rosario Leon, Juan Carlos Hinojosa Boyer, Lucia Ruiz, Graciela Meza

**Project Description:** Novel approaches to HIV-1 prevention warrant urgent evaluation. Tenofovir disoproxil fumarate (tenofovir or TDF), a nucleotide reverse transcriptase inhibitor, has been demonstrated to prevent transmission of simian immunodeficiency virus (SIV) when administered near the time of virus challenge. The efficacy of tenofovir chemoprophylaxis for HIV-1 prevention in people is not known. The primary goal of this proposal is to conduct a randomized blinded clinical trial evaluating the safety and efficacy of chemoprophylactic therapy using once daily tenofovir 300 mg to prevent HIV-1 acquisition in high-risk uninfected men who have sex with men (MSM).

**Significance:** Pre-exposure prophylaxis, or PrEP, is one of several experimental prevention interventions (including microbicides and vaccines) which could potentially provide additional modes of minimizing the risk of HIV infection.

**Project End Date:** August 2009